Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.
BACKGROUND
Polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) are important glycosyltransferases in cancer, but the clinical role of its individual isoforms is unclear. We investigated the clinical significance and survival relevance of one isoform, GalNAc-T6 in lung adenocarcinoma after curative resection.


RESULTS
GalNAc-T6 was identified in 27.8% (55/198) of patients, and statistically indicated advanced TNM stage (P = 0.069). Multivariate analysis showed GalNAc-T6 to be an independent predictor for reduced overall survival of patients (P = 0.027), and the result was confirmed with bootstraping techniques, and on line "Kaplan-Meier Plotter" and "SurvExpress" database analysis, respectively. Moreover, ROC curve demonstrated that GalNAc-T6 expression significantly improved the accuracy of survival prediction.


METHODS
With 198 paraffin-embedded tumor samples from lung adenocarcinoma patients, GalNAc-T6 expression was immunohistochemically assessed for the association with clinicopathological parameters. The prognostic significance was evaluated by Cox proportional hazards regression analysis with 1000 bootstraping. "Kaplan-Meier Plotter", "SurvExpress" database analysis, and receiver-operating characteristic (ROC) curve were performed to provide further validation.


CONCLUSIONS
GalNAc-T6 expression correlated significantly with advanced TNM stage, and independently predicted worse OS for lung adenocarcinoma.
Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China.|Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Zhi
Z
Li
Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.|Institute of Pathology, Medical University of Graz, Graz, Austria.|Department of Pathology, Field of Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Sohsuke
S
Yamada
Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China.
Ying
Y
Wu
Bio-Information Research Center, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Ke-Yong
KY
Wang
Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China.
Yun-Peng
YP
Liu
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.|Division of Thoracic Surgery, Saitama Cancer Center, Saitama, Japan.
Hidetaka
H
Uramoto
The President Laboratory, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.|Asahi-Matsumoto Hospital, Kitakyushu, Japan.
Kimitoshi
K
Kohno
Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.|Laboratory of Pathology, Fukuoka Wajiro Hospital, Fukuoka, Japan.
Yasuyuki
Y
Sasaguri
D000230:Adenocarcinoma / Q000201:enzymology / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000201:enzymology / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017350:N-Acetylgalactosaminyltransferases / Q000032:analysis*; D009367:Neoplasm Staging; D016016:Proportional Hazards Models
D017350:N-Acetylgalactosaminyltransferases; C121529:UDP-N-acetylgalactosamine polypeptide N-acetylgalactosaminyltransferase 6
GalNAc-T6; glycosylation; lung adenocarcinoma; overall survival; prognosis